...
Another Laboratory of OrigiMed Has Been Accredited by CAP...
OrigiMed Makes An Appearance at the 2023 American Society of Clinical ...
SHANGHAI, May 17, 2023 /PRNewswire/ -- Beijing Xisike Clinical Oncolog...
Chinese expert consensus on the diagnosis and treatment of thymic epit...
Chinese expert consensus on the diagnosis and treatment of HER2-altere...
Expert consensus on the diagnosis and treatment of NTRK gene fusion so...
Chinese expert consensus on the multidisciplinary management of pneumo...
The pan-cancer online clinic for NTRK gene fusion...
OnNovember 7th, during the 5th China International Import Expo, Ping A...
On September 22, 2022, Menarini, an Italian biopharmaceutical company,...
Extending the benefits of tumor molecular profiling for all cancer pat...
OrigiMed Co., Ltd. ("OrigiMed") announced that the company has signed ...
OrigiMed announced that the Human NTRK1/2/3 Genomic Alteration Testing...
OrigiMed, a China-based leading precision medicine company and Takeda,...
Bayer and OrigiMed (Shanghai) Co., Ltd. (referred to as "OrigiMed") to...
With fast advances in the medical industry, on May 11, 2019, the third...
OrigiMed (Shanghai) Co., Ltd., (OrigiMed) has formally announced the c...
On September 21, 2018, the CSCO precision medicine international sessi...
OrigiMed announces an agreement with Illumina in Shanghai, China. It w...
osteosarcoma...
ovarian metastasis from gastric cancer...
cholangiocarcinoma...